At Protagen, we are dedicated to the development of powerful diagnostic tools that aid successful therapeutic development and better treatment strategies for some of the most severe autoimmune diseases. Utilizing a personalized medicine approach, our powerful multi-marker assay technology SeroTag enables differential diagnosis and patient stratification in some of the most relevant diseases, such as Rheumatoid Arthritis, Systemic Lupus Erythematosus and Multiple Sclerosis. With our high-throughput disease and treatment marker development engine (SeroTag), we are uniquely positioned to develop innovative autoimmune diagnostics.This is evidenced by our broad development portfolio of novel diagnostic tests, secured by strong IP coverage and validated by proof-of concept studies in thousands of clinical samples.
We are committed to providing our customers and collaborators with exceedingly high levels of service, supporting them throughout the diagnostic test development and implementation process, and providing proactive and expert guidance.
Founded in 1997, Protagen began life as a protein analysis services company, as a spin-out from the Ruhr-University of Bochum. In 2002 Protagen moved to its current location in the BioMedical Center (BMZ) Dortmund.
2010 saw us strengthen our protein library and biomarker discovery capabilities, focusing on unmet diagnostic needs in autoimmune diseases by utilizing the power of autoantibodies. Our unique blend of experience and expertise in autoantibody serum screening, combined with the continuous improvement and optimization of biomarker development, has continued to push us forward, leading to the establishment of the SeroTag process in 2011.